Viiv Healthcare Uk (No.3) Limited

Viiv Healthcare is a pharmaceutical company specializing in innovative treatments for HIV and AIDS, committed to enhancing patient health and quality of life through advanced therapeutic solutions. Viiv Healthcare Uk (No. 3) Limited was founded in 2012 as a pharmaceutical entity focused on HIV treatment. It operates as a subsidiary within the ViiV Healthcare group, which is dedicated to providing specialized medical solutions.

The company's headquarters are located in Brentford, United Kingdom. The firm was established through a collaboration of established pharmaceutical entities, enhancing its research capabilities in HIV therapies. ViiV Healthcare is a specialized pharmaceutical company fully dedicated to the development, production, and distribution of innovative medicines for the treatment and management of HIV and AIDS. The company focuses on a diverse range of antiretroviral therapies designed to improve the health and quality of life for individuals living with HIV.

Their product offerings include a variety of medications that target HIV at different stages of infection, aiming to enhance patient adherence through simplified dosing regimens and improved tolerability. ViiV Healthcare serves a global client base, including healthcare providers, hospitals, and clinics, with a particular emphasis on communities disproportionately affected by HIV in regions such as North America, Europe, Sub-Saharan Africa, and Latin America. The company's commitment to research and innovation continues to bridge the gap between scientific advancements and their practical application in clinical settings, with a focus on patient-centered studies and community engagement initiatives. ViiV Healthcare generates revenue primarily through the sale of its antiretroviral medications to healthcare providers and institutions.

The transaction structure typically involves direct sales to hospitals and clinics, where healthcare professionals prescribe ViiV's medications to patients based on their clinical needs. This B2B model facilitates partnerships with healthcare facilities, ensuring broad access to essential HIV treatments. Revenue streams are bolstered by collaborations and partnerships with public health organizations and governments, aimed at expanding access to HIV care and prevention services. The pricing of ViiV's flagship products reflects the complexities of the pharmaceutical market, where costs are influenced by factors such as development expenses, market demand, and the need to ensure affordability for patients in various geographical markets.